Morgan Stanley analyst Daniel Duran raised the firm's price target on Lionsgate Studios to $14 from $11 and keeps an Overweight rating on the shares. GenAI has the potential to commoditize content, while proven IP "has value but must be nurtured," the analyst tells investors in a note on the media and entertainment group.
